See this page online at: http://www.biotechfocus.com/2011Issue2


  • Make this your homepage
  • Print this Page


Magazine

Sign up for your subscription and keep up-to-date.


Upcoming Events


Newsletters

Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.


Email Address

FEBRUARY 2011
Volume 14, Issue 2

Pushing Canadian infectious disease research to new heights
By Shawn Lawrence
Construction of the new International Vaccine Centre (InterVac), the newest facility of the Vaccine and Infectious Disease Organization, on the campus of the University of Saskatchewan is nearing completion. Scheduled to open later this month, the facility will be among the largest of its kind in the world, and by far the largest infrastructure investment in vaccines ever made by Canada.

Sustainable chemistry alliance, forging a new legacy for Sarnia-Lambton
By Shawn Lawrence
In the heart of Canada’s chemical valley, there is an exciting movement afoot.

Detecting innovation: Verisante and the path to its ingenious cancer diagnostic tool
By Christopher Rogers
The tool, known as the Verisante Aura™ uses a multimodality imaging and spectroscopy system originally invented at the BC Cancer Agency.

Finding an innovative way forward
By Don Enns, President Life Sciences British Columbia
To say the last couple of years have been challenging is not only an understatement but is also inherently obvious.

5 Important steps for extending the life of the world's arsenal of antibiotics
By Ron Najafi, PhD
On November 5th, 2010, The New York Times ran an article by Andrew Pollack titled “Antibiotics Research Subsidies Weighed by U.S.” It reported that government officials are considering offering financial incentives to the pharmaceutical industry to spur the development of vitally needed antibiotics.

Communicating to stakeholders: You have to tell it to sell it
By Carol Reynolds
Researchers uncover innovative discoveries in their labs, but unless they communicate their findings effectively, no one knows about them, nor can investors be inspired to continue to fund their research.